Pulmonary hypertension in chronic renal failure patients

American Journal of Nephrology

Volumn 28, Issue 6, 2008, Pages 990-997

  Abdelwhab, Saeed ^a   Elshinnawy, Samah ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Brain natriuretic peptide; Chronic renal failure complications; Hemodialysis complications; Pulmonary hypertension; Thromboxane

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THROMBOXANE B2;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD FLOW; CHRONIC KIDNEY FAILURE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DOPPLER ECHOCARDIOGRAPHY; DOPPLER FLOWMETRY; ECHOCARDIOGRAPHY; ENZYME IMMUNOASSAY; FEMALE; HEMODIALYSIS; HUMAN; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PULMONARY HYPERTENSION; RISK ASSESSMENT;

ADULT; AGED; ARTERIOVENOUS FISTULA; BLOOD PRESSURE; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; HYPERTENSION, PULMONARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; RADIOIMMUNOASSAY; THROMBOXANE B2;

EID: 47149099225     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000146076     Document Type: Article

References (49)

1. Locatelli F, Marcelli D, Conte F, et al: Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol Dial Transplant 2000;15:69-80.
2. Archer S, Rich S: Primary pulmonary hypertension: a vascular biology and translational research 'work in progress'. Circulation 2000;102:2781-2791.
3. Rubin LJ: Pathology and pathophysiology of primary pulmonary hypertension. Am J Cardiol 1995;75:51A-54A.
4. Yigla M, Nakhoul F, Sabag A, et al: Pulmonary hypertension in patients with end-stage renal disease. Chest 2003;123:1577-1582.
5. Kumbar L, Fein PA, Rafiq MA, Borawski C, Chattopadhyay J, Avram MM: Pulmonary hypertension in peritoneal dialysis patients. Adv Perit Dial 2007;23:127-131.
6. Adekunle L, Schmidt F, Quist J, Enriquez D, Nasser N, Ali A, Ogungbamigbe T, Iqbal P, Zahir M: Pulmonary hypertension in patients with ESRD. Chest Meet Abstr 2006;130:253S.
7. Havlucu Y, Kursat S, Ekmekci C, Celik P, Serter S, Bayturan O, Dinc G: Pulmonary hypertension in patients with chronic renal failure. Respiration 2007;74:503-510.
8. Rubin LJ: Pathology and pathophysiology of primary pulmonary hypertension. Am J Cardiol 1995;75:51A-54A.
9. Pastan S, Bailey J: Dialysis therapy. N Engl J Med 1998;338:1428-1436.
10. Okura H, Takatsu Y: High output failure as cause of pulmonary hypertension. Intern Med 1994;33:363-365.
11. Fathi R, Isbel N, Haluska B, Case C, Johnson DW, Marwick TH: Correlates of subclinical left ventricular dysfunction in ESRD. 2003;41:1016-1025.
12. Morris ST, McMurray JJ, Rodger RS, Jardine AG: Impaired endothelium-dependent vasodilatation in uremia. Nephrol Dial Transplant 2000;15:1194-1200.
13. Migliacci R, Falcinelli F, Imperiali P, Floridi A, Nenci GG, Gresele P: Endothelial dysfunction in patients with kidney failure and vascular risk factors: acute effects of hemodialysis. Ital Heart J 2004;5:371-377.
14. Shah R: Endothelins in health and disease. Eur J Intern Med 2007;18:272-282.
15. Leuchte HH, El Nounou M, Tuerpe JC, Hartmann B, Baumgartner RA, Vogeser M, Muehling O, Behr J: N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest 2007;131:402-409.
16. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, Loyd JE, American College of Chest Physicians: Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines Chest 2004;126:14S-34S.
17. Bouillon R, Coopmans W, Degroote DE: Immunoradiometric assay of parathyrin with polyclonal and monoclonal region-specific antibodies. Clin Chem 1990;36:271-276.
18. Schiller NB, Shah PM, Crawford M, American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardio - grams: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989;2:358-367.
19. Reisner SA, Azzam Z, Halmann M: Septal/ free wall curvature ratio: a noninvasive index of pulmonary arterial pressure. J Am Soc Echocardiogr 1994;7:27-35.
20. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S: Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40S-47S.
21. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbély A, Édes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL: How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-2550.
22. Roca-Tey R, Rivas A, Samon R, Ibrik O, Viladoms J: Study of vascular access by color Doppler ultrasonography. Comparison between delta-H and CDU methods in measuring VA blood flow rate. Nefrologia 2005;25:678-683.
23. Ishimura E, Okuno S, Taniwaki H, Kizu A, Tsuchida T, Shioi A, Shoji T, Tabata T, Inaba M, Nishizawa Y: Different risk factors for vascular calcification in end-stage renal disease between diabetics and nondiabetics: the respective importance of glycemic and phosphate control. Kidney Blood Press Res 2007;31:10-15.
24. Said SI: Mediators and modulators of pulmonary arterial hypertension. Am J Physiol 2006;291:L547-L558.
25. Van Albada ME, Schoemaker RG, Kemna MS, Cromme-Dijkhuis AH, van Veghel R, Berger RMF: The role of increased pulmonary blood flow in pulmonary arterial hypertension. Eur Respir J 2005;26:487-493.
26. Coskun M, Boyvat F, Bozkurt B: Thoracic CT findings in long-term hemodialysis patients. Acta Radiol 1998;40:181-186.
27. Matavulj AE, Kovacevic P, Veljkovic S, Rajkovaca Z, Djekic-Cadjo M, Ponorac N: Pulmonary function in chronic renal failure: effects of peritoneal dialysis and haemodialysis. Chest Meet Abstr 2005;128:395S-396S.
28. Mahiout A, Jörres A, Hiss R, Meinhold H, Kessel M: Effects of blood-dialyser interaction on prostaglandins in uraemic patients and in healthy man. Nephrol Dial Transplant 1987;2:546-550.
29. Wahl HG, Graf S, Renz H, Fassbinder W: Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem 2004;50:1071-1074.
30. Clerico A, Caprioli R, Del Ry S, Giannessi D: Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. J Endocrinol Invest 2001;24:24-30.
31. Nakhoul F, Yigla M, Gilman R, Reisner SA, Abassi Z: The pathogenesis of pulmonary hypertension in haemodialysis patients via arteriovenous access. Nephrol Dial Transplant 2005;20:1686-1692.
32. Amin M, Fawzy A, Hamid MA, Elhendy A: Pulmonary hypertension in patients with chronic renal failure; role of parathyroid hormone and pulmonary artery calcifications. Chest 2003;124:2093-2097.
33. Caramuru LH, Maeda NY, Bydlowski SP, Lopes AA: Age-dependent likelihood of in situ thrombosis in secondary pulmonary hypertension. Clin Appl Thromb Hemost 2004;10:217-223.
34. Chen YF, Oparil S: Endothelial dysfunction in the pulmonary vascular bed. Am J Med Sci 2000;320:223-232.
35. Morris ST, Jardine AG: The vascular endothelium in chronic renal failure. J Nephrol 2000;13:96-105.
36. Hyman AL: Effects of large increases in pulmonary blood flow on pulmonary venous pressure. J Appl Physiol 1969;27:179-185.
37. Naeije R: Pulmonary vascular resistance. A meaningless variable? Intensive Care Med 2003;29:526-529.
38. Clarkson MR, Giblin L, Brown A, Little D, Donohoe J: Reversal of pulmonary hypertension after ligation of a brachiocephalic arteriovenous fistula. Am J Kidney Dis 2002;40:E8.
39. Basile C, Lomonte C, Vernaglione L, Casucci F, Antonelli M, Losurdo N: The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients. Nephrol Dial Transplant 2008;23:282-287.
40. Fishman AP: Changing concepts of the pulmonary plexiform lesion. Physiol Res 2000;49:485-492.
41. Gurudevan SV, Malouf PJ, Auger WR, Waltman TJ, Madani M, Raisinghani AB, De-Maria AN, Blanchard DG: LV function in pulmonary hypertension. Abnormal left ventricular diastolic filling in chronic thromboembolic pulmonary hypertension: True diastolic dysfunction or left ventricular underfilling? J Am Coll Cardiol 2007;49:1334-1339.
42. Faraz HA, Shah MK, Qureshi TA, Mubarak KK: Pulmonary hypertension in end-stage renal disease: clinical and hemodynamic improvement with endothelin receptor antagonist bosentan. Chest Meet Abstr 2006;130:304S-305S.
43. Gao Y, Raj JU: Role of veins in regulation of pulmonary circulation. Am J Physiol 2005;288:L213-L226.
44. 2 on the canine and feline pulmonary vascular bed. J Pharmacol Exp Ther 1980;213:300-305.
45. 2 blood levels and incipient system clotting in heparin free hemodialysis. ASAIO J 1995;41:173-177.
46. 2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191. Circulation 1990;81:I42-I52.
47. Corboy JC, Walker RJ, Simmonds MB, Wilkins GT, Richards AM, Espiner EA: Plasma natriuretic peptides and cardiac volume during acute changes in intravascular volume in haemodialysis patients. Clin Sci 1994;87:679-684.
48. Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW: Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest 2006;129:417-425.
49. Wang AY, Lam CW, Yu CM, Wang M, Chan IH, Zhang Y, Lui SF, Sanderson JE: N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 2007;18:321-330.